

Highlights of This Issue 5915

SPECIAL FEATURES

CCR Translations

- 5917 **Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy**
William E. Carson III
- 5920 **Toward a Better Understanding of Race and Cancer**
Otis W. Brawley

CCR Drug Updates

- 5923 **Pazopanib in Renal Cell Carcinoma**
James E. Ward and Walter M. Stadler

Molecular Pathways

- 5928 **Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis**
Xin Lu and Yibin Kang
- 5936 **Targeting RET Receptor Tyrosine Kinase Activation in Cancer**
John E. Phay and Manisha H. Shah

Review

- 5942 **Resveratrol: Challenges in Translation to the Clinic — A Critical Discussion**
Lalita Subramanian, Sherry Youssef, Saswati Bhattacharya, Jason Kenealey, Arthur S. Polans and Paul R. van Ginkel

CCR Focus

- 5950 **Striving to Improve Outcomes in Oncology: Unmet Expectations in a Complex Disease**
Susan E. Bates

- 5951 **Translating Clinical Trials into Meaningful Outcomes**
Patricia M. LoRusso, Lowell E. Schnipper, David J. Stewart, Scott A. Boerner, Steven D. Averbuch and Walter Wolf
- 5956 **Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed In the Right Direction?**
Patricia M. LoRusso, Aparna B. Anderson, Scott A. Boerner and Steven D. Averbuch
- 5963 **Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past**
Christopher M. Booth
- 5972 **Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?**
Tito Fojo and David R. Parkinson
- 5981 **Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small**
Thomas J. Smith and Bruce E. Hillner
- 5987 **The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally**
William S. Dalton, Daniel M. Sullivan, Timothy J. Yeatman and David A. Fenstermacher
- 5997 **The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center**
Justin F. Klamerus, Suanna S. Bruinooge, Xiaobu Ye, Mandi L. Klamerus, Dorothy Damron, Dina Lansey, John C. Lowery, Luis A. Diaz Jr., Jean G. Ford, Norma Kanarek and Charles M. Rudin
- 6004 **Value and Cancer Care: Toward an Equitable Future**
Lowell E. Schnipper, Neal J. Meropol and Dan W. Brock

HUMAN CANCER BIOLOGY

- 6009 | **IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer**
Zhi Liu, Dingxie Liu, Ermal Bojdani, Adel K. El-Naggar, Vasily Vasko and Mingzhao Xing

CANCER THERAPY: PRECLINICAL

- 6019 | **Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model**
Ping Yu, Jason C. Steel, Meili Zhang, John C. Morris and Thomas A. Waldmann
- 6029 | **Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma**
Saadia A. Aziz, Lucia B. Jilaveanu, Christopher Zito, Robert L. Camp, David L. Rimm, Patricia Conrad and Harriet M. Kluger
- 6040 | **The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations**
Begoña Comin-Anduix, Thinle Chodon, Hooman Sazegar, Douglas Matsunaga, Stephen Mock, Jason Jalil, Helena Escuin-Ordinas, Bartosz Chmielowski, Richard C Koya and Antoni Ribas
- 6049 | **Microenvironmental Regulation of Glioblastoma Radioresponse**
Muhammad Jamal, Barbara H. Rath, Eli S. Williams, Kevin Camphausen and Philip J. Tofilon
- 6060 | **The Notch Target Hes1 Directly Modulates Gli1 Expression and Hedgehog Signaling: A Potential Mechanism of Therapeutic Resistance**
Karisa C. Schreck, Pete Taylor, Luigi Marchionni, Vidya Gopalakrishnan, Eli E. Bar, Nicholas Gaiano and Charles G. Eberhart
- 6071 | **A Hypoxia- and α -Fetoprotein-Dependent Oncolytic Adenovirus Exhibits Specific Killing of Hepatocellular Carcinomas**
Oh-Joon Kwon, Pyung-Hwan Kim, Steven Huyn, Lily Wu, Minjung Kim and Chae-Ok Yun

IMAGING, DIAGNOSIS, PROGNOSIS

- 6083 | **Genotypic Profiling of 452 Choroidal Melanomas with Multiplex Ligation-Dependent Probe Amplification**
Bertil Damato, Justyna A. Dopierala, Sarah E. Coupland
- 6093 | **Prognostic Value of Baseline [18 F] Fluorodeoxyglucose Positron Emission Tomography and 99m Tc-MDP Bone Scan in Progressing Metastatic Prostate Cancer**
Gustavo S.P. Meirelles, Heiko Schöder, Gregory C. Ravizzini, Mithat Gönen, Josef J. Fox, John Humm, Michael J. Morris, Howard I. Scher and Steven M. Larson
- 6100 | **Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study**
Katie M. O'Brien, Stephen R. Cole, Chiu-Kit Tse, Charles M. Perou, Lisa A. Carey, William D. Foulkes, Lynn G. Dressler, Joseph Geradts and Robert C. Millikan
- 6111 | **A Combination of Serum Markers for the Early Detection of Colorectal Cancer**
Norbert Wild, Herbert Andres, Wolfgang Rollinger, Friedemann Krause, Peter Dilba, Michael Tacke and Johann Karl

CANCER THERAPY: CLINICAL

- 6122 | **CD8+ Enriched "Young" Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma**
Mark E. Dudley, Colin A. Gross, Michelle M. Langhan, Marcos R. Garcia, Richard M. Sherry, James C. Yang, Giao Q. Phan, Udai S. Kammula, Marybeth S. Hughes, Deborah E. Citrin, Nicholas P. Restifo, John R. Wunderlich, Peter A. Prieto, Jenny J. Hong, Russell C. Langan, Daniel A. Zlott, Kathleen E. Morton, Donald E. White, Carolyn M. Laurencot and Steven A. Rosenberg
- 6132 | **Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers**
Raffit Hassan, Steven J. Cohen, Martin Phillips, Ira Pastan, Elad Sharon, Ronan J. Kelly, Charles Schweizer, Susan Weil and Daniel Laheru

- 6139 **Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine**
Steven K. Libutti, Giulio F. Paciotti, Adriana A. Byrnes, H. Richard Alexander, Jr., William E. Gannon, Melissa Walker, Geoffrey D. Seidel, Nargiza Yuldasheva and Lawrence Tamarkin
- 6150 **Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study**
Denis C. Talbot, Malcolm Ranson, Joanna Davies, Michael Lahn, Sophie Callies, Valérie André, Sunil Kadam, Michael Burgess, Christopher Slapak, Anna L. Olsen, Peter J. McHugh, Johann S. de Bono, Julian Matthews, Azeem Saleem and Patricia Price

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE


- 6159 **A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer**
Monika Graeser, Afshan McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salter, Nicholas Orr, Marina Parton, Ian E. Smith, Jorge S. Reis-Filho, Mitch Dowsett, Alan Ashworth and Nicholas Turner,
- 6169 **Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer**
Song Yao, William E. Barlow, Kathy S. Albain, Ji-Yeob Choi, Hua Zhao, Robert B. Livingston, Warren Davis, James M. Rae, I-Tien Yeh, Laura F. Hutchins, Peter M. Ravdin, Silvana Martino, Alan P. Lyss, C. Kent Osborne, Martin Abeloff, Gabriel N. Hortobagyi, Daniel F. Hayes and Christine B. Ambrosone

LETTERS TO THE EDITOR

- 6177 **Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Letter**
Cathy B. Moelans, Roel A. de Weger and Paul J. van Diest
- 6178 **Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Response**
Leona Downey and Robert Livingston
- 6179 **Do Rectal Cancer Patients with PIK3CA Mutations Benefit from Preoperative Radiotherapy with Regard to Local Recurrences?**
Youji He, Laura J. Van't Veer, Marta Lopez-Yurda, Cornelis J.H. van de Velde and Corrie A.M. Marijnen
- 6180 **Clinical Usefulness of Microarrays for Cancer Prognosis in 2010—Letter**
Serge Koscielny and Stefan Michiels
- 6181 **Statistical Evaluation of Clinical Usefulness of Microarrays for Cancer Prognosis Needs to be Placed in the Context of Clinical Reality—Response**
Weida Tong and Xiaohui Fan
- 6182 **Acknowledgment to Reviewers**

ABOUT THE COVER

Intracerebral xenograft initiated from the CD133⁺ glioblastoma stem-like cell line GBMJ1. At the initial signs of morbidity (94 days after implantation) a representative mouse was euthanized and the brain tumor prepared for histological analyses. This figure shows the immunofluorescent analyses of GFAP (red) and III tubulin (green) with nuclei counterstained with DAPI (blue) at 20x magnification. For details, see the article by Jamal and colleagues on page 6049 of this issue.



Clinical Cancer Research

16 (24)

Clin Cancer Res 2010;16:5915-6192.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/16/24>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/16/24>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.